At a glance
- Originator Merck & Co
- Class Osteoporosis therapies
- Mechanism of Action Bone resorption factor inhibitors; Integrin alphaVbeta3 antagonists; Osteoclast inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Postmenopausal osteoporosis
Most Recent Events
- 03 Oct 2006 Discontinued - Preclinical for Postmenopausal osteoporosis in USA (unspecified route)
- 07 Sep 1998 No-Development-Reported for Postmenopausal osteoporosis in USA (Unknown route)
- 10 Jul 1996 Preclinical development for Postmenopausal osteoporosis in USA (Unknown route)